| Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial A Sabchareon, D Wallace, C Sirivichayakul, K Limkittikul, ... The Lancet 380 (9853), 1559-1567, 2012 | 986 | 2012 |
| Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans SO Sow, BJ Okoko, A Diallo, S Viviani, R Borrow, G Carlone, M Tapia, ... New England Journal of Medicine 364 (24), 2293-2304, 2011 | 214 | 2011 |
| Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution FM LaForce, N Ravenscroft, M Djingarey, S Viviani Vaccine 27, B13-B19, 2009 | 214 | 2009 |
| Hepatitis B vaccination in infancy in The Gambia: protection: against carriage at 9 years of age S Viviani, A Jack, AJ Hall, N Maine, M Mendy, R Montesano, HC Whittle Vaccine 17 (23-24), 2946-2950, 1999 | 200 | 1999 |
| The meningitis vaccine project FM LaForce, K Konde, S Viviani, MP Préziosi Vaccine 25, A97-A100, 2007 | 194 | 2007 |
| Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults N Kshirsagar, N Mur, U Thatte, N Gogtay, S Viviani, MP Préziosi, C Elie, ... Vaccine 25, A101-A107, 2007 | 102 | 2007 |
| Dengue epidemiology in selected endemic countries: factors influencing expansion factors as estimates of underreporting NT Toan, S Rossi, G Prisco, N Nante, S Viviani Tropical medicine & international health 20 (7), 840-863, 2015 | 92 | 2015 |
| 20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer S Viviani, P Carrieri, E Bah, AJ Hall, GD Kirk, M Mendy, R Montesano, ... Cancer Epidemiology Biomarkers & Prevention 17 (11), 3216-3223, 2008 | 83 | 2008 |
| Control of hepatocellular carcinoma through hepatitis B vaccination in areas of high endemicity: perspectives for global liver cancer prevention A Plymoth, S Viviani, P Hainaut Cancer letters 286 (1), 15-21, 2009 | 82 | 2009 |
| Double-blind study comparing the immunogenicity of a licensed DTwPHib-CRM197 conjugate vaccine (Quattvaxem™) with three investigational, liquid formulations using lower doses … E Tamm, A Veronese, M Contorni, S Meriste, P Nacci, S Viviani Vaccine 23 (14), 1715-1719, 2005 | 79 | 2005 |
| Influenza viruses and vaccines: the role of vaccine effectiveness studies for evaluation of the benefits of influenza vaccines CM Trombetta, O Kistner, E Montomoli, S Viviani, S Marchi Vaccines 10 (5), 714, 2022 | 54 | 2022 |
| Childhood vaccination coverage in Italy: results of a seven-region survey Italian Vaccine Coverage Survey Working Group Bull WHO 72, 885-95, 1994 | 47 | 1994 |
| Effect of aluminum adjuvants on safety and immunogenicity of Haemophilus influenzae type b‐CRM197 conjugate vaccine G Kanra, S Viviani, K Yurdakök, E Özmert, A Anemona, SL Yalçİn, ... Pediatrics international 45 (3), 314-318, 2003 | 46 | 2003 |
| Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection S Marchi, S Viviani, EJ Remarque, A Ruello, E Bombardieri, V Bollati, ... PLoS One 16 (7), e0253977, 2021 | 44 | 2021 |
| Successful African introduction of a new Group A meningococcal conjugate vaccine: Future challenges and next steps FM LaForce, M Djingarey, S Viviani, MP Preziosi Human vaccines & immunotherapeutics 14 (5), 1098-1102, 2018 | 38 | 2018 |
| Safety and immunogenicity of a new fully liquid DTPw-HepB-Hib combination vaccine in infants G Kanra, A Kara, O Demiralp, M Contorni, AK Hilbert, C Spyr, S Viviani Human Vaccines 2 (4), 155-160, 2006 | 38 | 2006 |
| Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 … P Pitisuttithum, K Chokephaibulkit, C Sirivichayakul, S Sricharoenchai, ... The Lancet Infectious Diseases 18 (11), 1260-1268, 2018 | 34 | 2018 |
| Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2–10 years: a phase II/III double-blind randomized controlled trial S Hirve, A Bavdekar, A Pandit, S Juvekar, M Patil, MP Preziosi, Y Tang, ... Vaccine 30 (45), 6456-6460, 2012 | 34 | 2012 |
| A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3 … S Sricharoenchai, C Sirivichayakul, K Chokephaibulkit, P Pitisuttithum, ... The Lancet Infectious Diseases 18 (1), 58-67, 2018 | 30 | 2018 |
| Investigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or A/C polysaccharide vaccine in adults H Findlow, BD Plikaytis, A Aase, MC Bash, H Chadha, C Elie, G Laher, ... Clinical and Vaccine Immunology 16 (7), 969-977, 2009 | 29 | 2009 |
